Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$20.03 USD
+0.05 (0.25%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $20.04 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum A VGM
Brokerage Reports
0 items in cart
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 161 - 180 ( 722 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Preannounced 2Q Solid Exparel Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q2 Preliminary EXPAREL Sales Beat Par for the Course as Growth Continues
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Eurofarma Deal Provides Glimpse into Global Expansion Strategy
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
May 2021 Preliminary Net Product Revenues Tracking Above Consensus
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
EXPAREL Phase 3 STRIDE Study Misses Primary Endpoint; Selloff Overdone
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
1Q21: Strong Quarter With View to Post-COVID Tailwinds, and New Growth Drivers Ahead; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q1; Long-Term Growth; Phase 3 Lower Extremity Nerve Block Data in May
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Expanding Pipeline with First Foray into Regenerative Medicine
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department